. The detection of pathogen-derived nucleic acids is a central strategy by which the host senses infection and initiates protective immune responses 5, 6 . Cyclic GMP-AMP synthase (cGAS) is a double-stranded DNA sensor 7, 8 . It catalyses the synthesis of cyclic GMP-AMP (cGAMP) [9] [10] [11] [12] , which stimulates the induction of type I interferons through the STING-TBK1-IRF-3 signalling axis [13] [14] [15] . STING oligomerizes after binding of cGAMP, leading to the recruitment and activation of the TBK1 kinase 8, 16 . The IRF-3 transcription factor is then recruited to the signalling complex and activated by TBK1 8,17-20 . Phosphorylated IRF-3 translocates to the nucleus and initiates the expression of type I interferons 21 . However, the precise mechanisms that govern activation of STING by cGAMP and subsequent activation of TBK1 by STING remain unclear. Here we show that a conserved PLPLRT/SD motif within the C-terminal tail of STING mediates the recruitment and activation of TBK1. Crystal structures of TBK1 bound to STING reveal that the PLPLRT/SD motif binds to the dimer interface of TBK1. Cellbased studies confirm that the direct interaction between TBK1 and STING is essential for induction of IFNβ after cGAMP stimulation. Moreover, we show that full-length STING oligomerizes after it binds cGAMP, and highlight this as an essential step in the activation of STING-mediated signalling. These findings provide a structural basis for the development of STING agonists and antagonists for the treatment of cancer and autoimmune disorders.
, the Ser366Ala mutation abolishes activation of the IFNβ reporter and phosphorylation of IRF-3 (Fig. 1a, b) . By contrast, the Thr376Ala and Ser379Ala mutations do not affect activation of TBK1 or IRF-3 (Fig. 1b) . Notably, deletion of the nine C-terminal residues of STING (ΔC9) abolishes activation of the reporter and phosphorylation of IRF-3 (Fig. 1a, b) . In addition, deletion of these residues impairs activation of TBK1 (Fig. 1b) . Confocal microscopy analysis revealed that the truncated STING mutant still translocates to perinuclear punctate structures after cGAMP stimulation (Fig. 1c, Extended Data Fig. 1d ). However, TBK1 does not co-translocate into these puncta with ΔC9 STING (Fig. 1c) . Furthermore, immunoprecipitation assays indicate that both wild-type STING and the Ser366Ala mutant bind TBK1; however, deletion of the nine C-terminal residues abolishes TBK1 binding and phosphorylation (Fig. 1d ).
To test whether STING binds TBK1 directly, we expressed several biotin-labelled STING truncation mutants (Extended Data Fig. 2a, b) and conducted TBK1 binding studies by surface plasmon resonance (SPR) analysis (Extended Data Table 1 ). We observed that unphosphorylated STING binds TBK1 directly with relatively low affinity (Extended Data Fig. 2c, d ). The binding affinity does not change notably in the presence of cGAMP (Extended Data Fig. 2e , f). However, after phosphorylation, STING binds to TBK1 at almost 20 times higher affinity (Fig. 1e, Extended Data Fig. 2g ). The binding affinity does not change notably in the absence of cGAMP (Extended Data Fig. 2h, i ). In addition, phosphorylation of TBK1 does not affect its binding affinity with STING (Extended Data Fig. 2j ). To map the TBK1-binding site, we conducted binding studies with several truncated forms of STING (Extended Data Fig. 2a, b) . We observed that truncation of the C-terminal 9 or 37 residues of STING abolish TBK1 binding (Fig. 1e , f, Extended Data Fig. 2g, k) . By contrast, peptides containing the C-terminal 37 or 14 residues of STING are fully capable of binding TBK1 (Fig. 1f, Extended Data Fig. 2k, l) .
To determine the exact STING residues that contribute to binding of TBK1, we generated several STING mutants ( . These studies showed that the Leu374Ala mutation disrupts binding of TBK1 (Fig. 2a, Extended Data Fig. 3f ). However, this mutation does not affect binding of IRF-3 (Extended Data Fig. 3m ). In addition, the Arg375Ala and Phe378Ala mutations reduce the binding affinity by 30-and 20-fold, respectively (Fig. 2a, Extended Data Fig. 3g, j) . The Leu372Ala and Pro373Ala mutations reduce the binding affinity by about tenfold (Fig. 2a, Extended Data Fig. 3d , e). The Pro371Ala, Thr376Ala, Asp377Ala and Ser379Ala mutations only reduce the binding affinity by 3-6-fold (Fig. 2a, Extended Data Fig. 3c , h, i, k). By contrast, mutations Lys370Ala and Ser366Ala do not affect binding of TBK1 (Fig. 2a, Extended Data Fig. 3b, l) . Sequence alignment of STING from 60 species (Extended Data Table 2) reveals that the C-terminal residues of STING are highly conserved (Extended Data  Fig. 3n ). Therefore, these mutagenesis and binding studies identified a highly conserved PLPLRT/SD motif that mediates the recruitment of TBK1 by STING (Extended Data Fig. 3n ). On the basis of these results, we also identified a high-affinity phosphomimetic mutant of STING (Thr376Glu/Phe378Met/Ser379Trp, referred to hereafter as EMW; Extended Data Fig. 3o , Extended Data Table 1 ).
To determine the functional roles of the nine C-terminal residues of STING, we mutated each of them to alanine and conducted IFNβ reporter assays (Fig. 2b) . These assays showed that truncation of the nine C-terminal residues of STING (ΔC9) or mutation Leu374Ala disrupts the activation of the luciferase reporter (Fig. 2b) . Mutation Arg375Ala reduces the reporter activity by about 50% (Fig. 2b) . Mutations Pro371Ala, Thr376Ala and Asp377Ala reduce the reporter signal by about 30% (Fig. 2b) . By contrast, mutations Lys370Ala,
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Leu372Ala, Pro373Ala, Phe378Ala and Ser379Ala only reduce the signals slightly (Fig. 2b) . Notably, the high-affinity EMW mutant stimulates a similar level of signal as wild-type STING (Fig. 2b) . As a control, mutation Ser366Ala disrupts activation of the reporter (Extended Data  Fig. 3p ). In addition, the reporter assays showed that wild-type STING induces a faster response to cGAMP than the Thr376Ala mutant, indicating that phosphorylation of the PLPLRT/SD motif is needed for optimal signalling by STING (Extended Data Fig. 3q ).
Next, we tested how these mutations affect STING-mediated signalling in cells. Western blot analysis showed that TBK1, STING and IRF-3 are phosphorylated after cGAMP stimulation of cells expressing wild-type STING (Fig. 2c) . Truncation of the nine C-terminal residues or the Leu374Ala mutation abolished phosphorylation of TBK1, STING and IRF-3 (Fig. 2c) . By contrast, the Ser366Ala mutation only abolished IRF-3 phosphorylation, but did not affect activation of TBK1 (Extended Data Fig. 3r ). The Arg375Ala mutation markedly reduces the phosphorylation of TBK1, STING and IRF-3 (Fig. 2c) . By contrast, the Pro371Ala, Leu372Ala, Asp377Ala and Phe378Ala mutations only slightly reduce TBK1, STING and IRF-3 phosphorylation (Fig. 2c) . Mutations Lys370Ala, Pro373Ala, Thr376Ala and Ser379Ala, and the EMW mutation, do not affect the activation of TBK1, IRF-3 or STING (Fig. 2c) . Consistent with these results, immunoprecipitation showed that these mutations affect binding of TBK1 by STING in cells (Fig. 2d ). Moreover, we tested whether proximity of the IRF-3 binding pLxIS motif (p, hydrophilic residue; x, any residue; S, phosphorylation site) and the TBK1 binding PLPLRT/SD motif is necessary for STING-mediated signalling. We observed that insertion of six residues (GSGSGS) between these two motifs does not affect activation of the IFNβ reporter (Fig. 2e) . In addition, we tested whether the two motifs on separate STING molecules could support signalling. We co-transfected the cells with the Ser366Ala and Leu374Ala mutants and observed that together, these two mutants support activation of the IFNβ reporter (Fig. 2f) . Western blot showed that TBK1 and IRF-3 are activated in cells co-transfected with the Ser366Ala and Leu374Ala mutants, but not in cells transfected with either the Leu374Ala or the Ser366Ala mutant (Fig. 2g) .
To decipher the molecular basis of TBK1 recruitment by STING, we determined the crystal structures of TBK1 bound to the STING CTT and CTD (Fig. 3, Extended Data Fig. 4 , Extended Data Table 3 ). The structure of TBK1 bound to the STING CTT showed that a TBK1 dimer binds to two peptides from the STING CTT (Fig. 3a) . Each STING peptide interacts with two TBK1 molecules simultaneously, forming a 2:2 complex (Fig. 3a) . The STING-binding sites are located at the interface between the N-lobe of the kinase domain and the scaffold and dimerization domain of two TBK1 molecules (Fig. 3a, b) . The STING CTT adopts an extended random coil structure that binds Letter reSeArCH TBK1 mainly through hydrophobic interactions and hydrogen bonds via the PLPLRT/SD motif (Fig. 3c) . The main-chain carbonyl group of Lys370, the amide group of Leu372, and the carbonyl group of Pro373 interact with the side chains of Lys584, Gln581 and Tyr577 by hydrogen bonds (Fig. 3c) . The side chain of Leu374 reaches into a hydrophobic pocket defined by residues Leu8, Arg27, Lys29, Asn578, Gln581, Ile582 and Phe585, anchoring the PLPLRT/SD motif to its binding groove (Fig. 3c) . In addition, the amide group of Leu374 also forms a hydrogen bond with the carbonyl of Lys29. Arg375 forms two hydrogen bonds with the side chain of Asn578 via its backbone amide and carbonyl groups (Fig. 3c) . Superposition of the structures of the CTT of STING bound to mouse TBK1 and the CTD of STING EMW mutant bound to human TBK1 reveals that the C-terminal residues of the EMW mutant bind to human TBK1 in a similar fashion (Fig. 3d) . Glu376, which mimics phosphorylated Thr376, interacts with the side chain of Lys29 by electrostatic interaction and with the side chain of Ser3 through a hydrogen bond (Fig. 3d, Extended Data Fig. 4f ), explaining why phosphorylated STING binds TBK1 with higher affinity.
To confirm that the binding surface of TBK1 identified through the structural analyses is involved in its recruitment by STING, we expressed nine mutants of TBK1 for binding studies (Fig. 4a , Extended Data Fig. 5a-g ). These studies showed that mutations Leu8Ala, Lys29Ala, Tyr577Ala, Asn578Ala and Ile582Ala abolish the interactions between TBK1 and phosphorylated STING (Fig. 4a , Extended Data Fig. 5a-d, f) . In addition, mutations Gln581Ala and Lys584Ala also reduce the binding affinity by almost 20-fold (Fig. 4a, Extended Data  Fig. 5e, g ). By contrast, mutations Pro404Ala and Phe585Ala do not affect binding (Fig. 4a, Extended Data Fig. 5c, d ). Similar results were obtained using mouse TBK1 for the binding studies (Fig. 4a ). Next, we tested how these mutations of TBK1 affect STING-mediated signalling. We generated TBK1-knockout HEK293T cells, which were deficient in STING-mediated signalling, but were responsive after TBK1 transfection (Fig. 4b, Extended Data Fig. 5h-j) . The Pro404Ala and Phe585Ala mutations only have minor effects on signalling (Fig. 4b) . By contrast, mutations Arg27Ala, Lys29Ala, Ile582Ala and Lys584Ala reduce the signals by about 40% (Fig. 4b) . Mutations Leu8Ala and Tyr577Ala reduce the signals by over 60% (Fig. 4b) . Mutations Asn578Ala and Gln581Ala reduce the signals to a similar level to that of the kinase inactive Ser172Ala mutant (Fig. 4b) . Western blot showed that mutations Leu8Ala, Arg27Ala, Tyr577Ala, Asn578Ala, Gln581Ala and Ile582Ala markedly reduced the phosphorylation of TBK1, STING and IRF-3 (Fig. 4c) . Although mutations Lys29Ala and Lys584Ala also reduced TBK1 and STING phosphorylation, they only have minor effects on IRF-3 phosphorylation (Fig. 4c) . By contrast, mutations Pro404Ala and Phe585Ala only have minor effects on the phosphorylation of TBK1, STING and IRF-3 (Fig. 4c) . Moreover, immunoprecipitation confirmed that these residues are crucial in the recruitment of TBK1 by STING in cells (Extended Data Fig. 5k) .
Although the CTT of STING can mediate activation of IRF-3 in an in vitro reconstitution system 16 , expression of the CTD of STING alone is not sufficient to activate STING-mediated signalling in cells 22 . P371A  L372A  P373A  L374A  R375A  T376A  D377A  F378A  S379A Letter reSeArCH (Extended Data Fig. 6a, b) . However, in the presence of cGAMP, STING forms stable oligomers with an estimated mass of approximately 400 kDa (Extended Data Fig. 6a, b) . SDS-PAGE analysis of crosslinked STING oligomers reveals a protein band of around 360 kDa (Extended Data Fig. 6c, d ). In addition, size-exclusion chromatography and multiangle light scattering (SEC-MALS) analysis also confirmed the formation of the STING oligomers (Extended Data Fig. 6e ). On the basis of these observations, we estimate that four to five STING dimers are present in the peak fractions of the STING-cGAMP complex. To provide additional evidence of STING oligomerization after binding of cGAMP, we cross-linked the STING oligomer and imaged the sample by cryo-electron microscopy (cryo-EM) (Extended Data Fig. 6f ). Both the raw images and the 2D averages show that the STING-cGAMP complex forms oligomers (Extended Data Fig. 6f, g ). We have generated an approximately 12 Å resolution map of the STING oligomer, which reveals that the STING dimers probably stack against each other sideby-side to form the oligomers (Extended Data Fig. 6h-j) . On the basis of results from previous mutagenesis studies of mouse STING 22 , we identified a STING mutant (Glu68Ala/Glu69Ala/His74Ala/Ser75Ala/ Arg76Ala) that does not form oligomers in the presence of cGAMP (Extended Data Fig. 6k-m) and is not capable of supporting STINGmediated signalling (Extended Data Fig. 6n, o) . Confocal microscopy revealed that this STING mutant does not translocate to the perinuclear punctate structures or co-localize with TBK1 after cGAMP stimulation, whereas other functional mutants behave similarly to wild-type STING (Extended Data Fig. 6p ). Consistent with these findings, a recent study showed that the Glu68Ala and Glu69Ala mutations abolish STING-mediated signalling and STING oligomerization in cells treated with cGAMP 23 . On the basis of our results, we propose a molecular model of STINGmediated signalling (Extended Data Fig. 7) . First, binding of cGAMP induces the oligomerization of STING. Next, TBK1 is recruited to the STING oligomers via its C-terminal PLPLRT/SD motif and is activated by induced proximity in trans. Activated TBK1 phosphorylates STING at the PLPLRT/SD motif, facilitating further recruitment and activation of TBK1. Phosphorylation of STING at the pLxIS motif allows STING to recruit IRF-3, bringing IRF-3 and TBK1 into proximity and thus facilitating activation of IRF-3. Because simultaneous binding of TBK1 and IRF-3 to a single STING molecule is not required for activation of IRF-3, it is likely that the proximity of IRF-3 and TBK1 induced by adjacent STING molecules in the STING oligomers mediates the activation of IRF-3 by TBK1. This study provides a structural framework for the development of conceptually new approaches to inhibit deleterious STING-mediated immune responses in autoimmune and inflammatory disorders.
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MEthodS
Mass spectrometry. We expressed a short peptide containing the 22 C-terminal residues human STING as SUMO-fusion. The peptide was purified and phosphorylated with TBK1. The phosphorylated peptide was analysed using a liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/ MS) system, consisting of a Dionex Ultimate 3000 LC system (with an Acclaim PepMap 100 C18 column from Thermo) coupled to a Thermo Orbitrap Fusion mass spectrometer. Liquid chromatography system solvents were water with 0.1% formic acid (mobile phase A) and acetonitrile with 0.1% formic acid (mobile phase B). The peptides were eluted over a 60-min gradient from 2% B from 0 to 5 min, 2% to 45% from 5 to 37 min, 45% to 90% from 38 to 46 min, and down to 2% from 46 to 60 min at a flow rate of 0.4 μl min −1
. The mass spectrometer ion source was set to have a spray voltage of 2.3 kV, ion transfer tube temperature of 275 °C, the scan range was m/z 400-1,600 with a resolution of 120,000. MS/MS acquisition was performed with 3-s cycle time. The intensity threshold was set to 5,000; ions with charge states 2+ to 6+ were sequentially fragmented by electron transfer dissociation (ETD) with 100 ms ETD reaction time and 200,000 ETD reagent target, followed by high energy collisional dissociation (HCD) with a normalized collision energy (NCE) of 40%. The dynamic exclusion duration was set as 60 s. Raw data were analysed using the Thermo Proteome Discoverer (v.2.1.0.81) software platform. The mass spectrometry data were analysed using SEQUEST with the following parameters: the protein sequence database contained only the ST358 sequence, dynamic (or variable) modifications included protein N-terminal acetylation, oxidation, serine, threonine and tyrosine phosphorylation. Mass tolerances for precursor ions was set to 10 p.p.m., and fragment ions set to Δ0.6 Da. Limits for peptide length searched range from 6 to 144, maximum ΔCn is set to 0.05. Maximum number of allowed missed cleavages is 2. Cell culture. HEK293T cells were obtained from ATCC (CRL-3216), cultured in DMEM (1×) plus GlutaMAX medium (Gibco) supplemented with 10% fetal bovine serum (Gibco), penicillin (100 U ml ) and streptomycin (100 μg ml ) and streptomycin (50 μg ml
−1
). The cells were cultured in a 37 °C incubator containing a humidified atmosphere of 8% CO 2 on an orbital shaker rotating at 130 r.p.m. All cell lines were kept at low passages to maintain their identity. The expression of STING and/or TBK1 in all cell lines was checked routinely to ensure they are the same as the original cell line. All cell lines tested negative for mycoplasma contamination. IFNβ luciferase reporter assays. The cDNA encoding human STING and TBK1 were cloned into a pcDNA3.1 (-) vector. All mutations were generated by sitedirected mutagenesis and confirmed by DNA sequencing. HEK293T cells were seeded in CoStar White 96-well plate (Corning) at 4 × 10 4 cells per well and cultured at 37 °C with 5% CO 2 . After 24 h, the cells were transfected with indicated amounts of pcDNA3.1-hSTING plasmids, IFNβ firefly luciferase reporter plasmid (20 ng per transfection) and phRL-TK-Renilla luciferase plasmid (2 ng per transfection) using the transfection reagent Lipofectamine 2000 (Invitrogen) according to the manufacture's manual. Empty pcDNA3.1 (-) plasmid was used as transfection control and also added to normalize the amount of DNA in each transfection. The cells were treated with 30 μg ml −1 cGAMP for 24 h after transfection. After 16 h stimulation, the cells were analysed using the Dual-Glo Luciferase report assay kit (Promega) and detection of the luminescent signals was performed with a BioTek Synergy HTX Multi-Mode microplate reader. IFNβ luciferase reporter assays using the TBK1-knockout HEK293T cells were performed in a similar way. The TBK1-knockout cells were transfected with indicated amounts of pcD-NA3.1-hSTING plasmid and/or pcDNA3.1-hTBK1 plasmid, IFNβ firefly luciferase reporter plasmid (10 ng per transfection) and phRL-TK-Renilla luciferase plasmid (2 ng per transfection). The relative firefly luciferase activity was normalized by the Renilla luciferase activity. The relative IFNβ reporter fold of induction represents the ratio normalized to the negative control plasmid values with the same treatment. Statistical analyses were carried out using Microsoft Excel. All data are presented as mean ± s.e.m. A two-tailed Student's t-test assuming equal variants was used to compare two groups. The statistical significance between the indicated samples is designated as * P < 0.05, * * P < 0.01, * * * P < 0.001, or not significant (P > 0.05). No statistical methods were used to predetermine sample size. Western blot. After transfection with pcDNA3.1-hSTING and/or pcDNA3.1-hTBK1 plasmids and stimulation with cGAMP, wild-type or TBK1-knockout HEK293T cells were washed and suspended in 1× PBS. After centrifugation, the cells were lysed in 200 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% Nonidet P-40 supplemented with one complete EDTA-free protease inhibitor mixture tablet (Roche) and one PhosSTOP phosphatase inhibitor mixture tablet (Roche) for each 10 ml of lysis buffer. The proteins were resolved using 10% SDS-PAGE gel and transferred to PVDF membrane for incubating with the primary antibodies. The primary antibodies used in the western blot analysis are as follows, anti-STING (Cell Signaling, 13647, 1:1,000), anti-STING phospho-Ser366 (Cell Signaling, 85735, 1:1,000), anti-TBK1 (Cell Signaling, 3013, 1:1,000), anti-TBK1 phospho-Ser172 (Cell Signaling, 5483, 1:1,000), anti-IRF-3 (Cell Signaling, 4302, 1:1,000), anti-IRF-3 phospho-Ser386 (Abcam, ab76493, 1:2,500), anti-Flag M2-Peroxidase (Sigma, A8592, 1:2,000) and anti-actin (Thermo Fisher Scientific, MA5-11869, 1:4,000). After incubation with the primary antibodies overnight at 4 °C, the membrane was further incubated with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 2 h. Detection of the target proteins was performed with a ChemiDoc MP Imaging System (Bio-Rad) using the Western Lightening Plus ECL kit (PerkinElmer) according to the manufacturer's protocol. For immunoprecipitation, the cell lysates were centrifuged at 20,000g for 10 min. The supernatant were incubated with anti-FLAG-M2 agarose affinity gel (Sigma, A2220) for 1 h at 4 °C. The proteins bound to the agarose beads were washed three times with TBS buffer (50 mM Tris, 150 mM NaCl, pH 7.4) and eluted by boiling with 1× SDS-PAGE sample buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% (v/v) glycerol, and 0.002% bromphenol blue and 10 mM dithiothreitol (DTT)) for 5 min. The samples were analysed using 10% SDS-PAGE gel. Immunocytochemistry. HEK293T cells grown on poly-l-lysine coated glass coverslips in 12-well plates for 24 h and were transfected with equal amount of wild-type or mutant STING plasmids, respectively. The transfection mixture was combined plasmid DNA with dilution Lipofectamine 2000 in Opti-MEM medium (Gibco). After incubation for 24 h, the medium was replaced with fresh growth medium with or without 30 μg ml −1 cGAMP. After incubation for 16 h, cells were washed with PBS, fixed using 4% paraformaldehyde in PBS for 10 min at room temperature and permeabilized with PBST (0.5% Triton X-100 in PBS). Cells were washed and blocked with 5% fetal bovine serum in PBST, followed by overnight incubation with primary antibodies, anti-STING (Cell Signaling, 13647, 1:200) and anti-TBK1 (GeneTex, GTX12116, 1:200). Cells were then washed three times by PBS and incubated with Alexa 488-conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch, 711-545-152, 1:1,000) and Alexa 555-conjugated donkey anti-Mouse IgG antibody (Thermo Fisher Scientific, A31570, 1:1,000) for 1 h at room temperature. The coverslips were then washed with PBS, mounted on slides with ProLong Gold antifade reagent with 4′-6-diamidino-2-phenylindole (DAPI) and imaged using a Nikon-Ti Fluorescence microscope. Protein expression and purification. Constructs of human STING were cloned into a modified pET28(a) vector with an N-terminal Avi-His6-SUMO tag. For protein quantification, the mutation Val343Trp was introduced into human STING C-terminal tail (residue 342-379). All the proteins were expressed in BL21 (DE3) cells in M9 medium. The cDNA encoding human IRF-3 (residue 189-427) was cloned into another modified pET28(a) vector with an N-terminal His6-SUMO tag. IRF-3 was also expressed in BL21 (DE3) cells in regular LB medium (BD). When OD 600 reached 1.0, the cells were induced with 0.4 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) and cultured overnight at 16 °C. The proteins were purified using the protocol described previously 24 . In brief, the proteins were first purified using a nickel-NTA column. The SUMO tag was then cleaved using SUMO protease and removed using a nickel-NTA column. The proteins were further purified by gel filtration chromatography using Superdex75 or 200 (16/60 GL) columns (GE Healthcare). The Se-methionine substituted human STING was expressed in M9 medium supplemented with selenomethionine (Acros Organics) and purified as described for the wild type protein. Human and mouse TBK1 (residue 1-657) were expressed in sf9 insect cells after infection with recombinant baculovirus and purified as described previously 25 . Biotin-labelled-AviHis6-SUMO proteins and peptides were also expressed in BL21 (DE3) cells in M9 medium, with the exception of the biotin-labelled Avi-His6-SUMO-GFP nanobody, which was expressed in regular LB medium. The cells were co-transformed with the pET28(a) plasmids coding for the target proteins and the pBirAcm plasmid coding for BirA and induced with 0.4 mM IPTG in the presence of 5 μg ml −1 biotin and cultured at 16 °C overnight. The SUMO fusion proteins and peptides were first purified using a nickel-NTA column and further purified on a Superdex75 or 200 column (GE Healthcare).
Full-length human STING was cloned into pEGFP-N1 plasmid with a green fluorescent protein (GFP) tag attached to the C terminus of STING. A thrombin cleavage site was inserted between STING and GFP. FreeStyle 293-F cells were seeded into fresh FreeStyle 293 expression media with a final density of 1.0 × 10 6 cells ml −1 and incubated at 37 °C, 8% CO 2 , 130 r.p.m. After 24 h, 1 mg pEGFP-N1-STING plasmids, 2 mg of linear PEI25000 (Polysciences, Inc.) were mixed into 100 ml 1 × PBS and incubated at room temperature for 20 min. Then, the mixture was added into 1L FreeStyle 293-F cells. After 2 days, the cells were pelleted at 3000 rpm for 5 min. The pellets were resuspended in 40 ml pre-chilled lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% n-dodecyl-β-d-maltoside (DDM)) containing the protease cocktail inhibitors (Roche), sonicated for 3 cycles and shaked gently at 4°C for 2 h. After centrifugation at 16000 rpm for 30 min, the supernatant was mixed Letter reSeArCH with 500 μl streptavidin agarose beads (EMD Millipore), which have been coupled with biotin-labelled Avi-SUMO-GFP nanobody. After shaking at 4°C for another 2 h, the beads were pelleted and washed with pre-chilled washing buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% DDM). Finally, the beads were resuspended in 500 μl washing buffer and SUMO protease was added to cleave the target protein from the beads. The eluted protein was incubated with thrombin at 4 °C overnight and further purified using a Superose 6 increase 10/300 GL column (GE Healthcare). All mutants of STING and TBK1 were generated using the QuikChange sitedirected mutagenesis kit (Agilent) or a PCR-based technique with appropriate primers. T he sequences of the plasmids were confirmed by plasmid DNA sequencing. Phosphorylation of STING. Biotin-labelled Avi-His6-SUMO-STING CTD and CTT peptides were phosphorylated using glutathione S-transferase (GST)-tagged mTBK1 in a reaction buffer containing 20 mM HEPES, pH 7.5, 10 mM MgCl 2 , 100 mM NaCl, 5 mM ATP, 0.1 mM Na 3 VO 4 , 5 mM NaF and 5 mM DTT. The target proteins were diluted to 1 mg ml −1 in the reaction buffer and mixed with GSTmTBK1 in a 10:1 (w/w) ratio. After 24 h incubation at 27 °C, the phosphorylated proteins were purified using a Superdex200 10/300 GL column (GE Healthcare) eluted with a buffer containing 20 mM Tris, 150 mM NaCl at pH 7.5. SPR. The SPR binding studies were performed with a Biacore X100 SPR instrument (GE Healthcare). Biotin CAPture Kit (GE Healthcare) was used for binding analysis in 1× HBS-EP+ buffer (GE Healthcare). Biotin-labelled Avi-His6-SUMOfusion proteins or peptides were captured on the Sensor Chip CAP using Biotin CAPture reagent. TBK1 and IRF-3 in a series of twofold dilutions were flowed through the sensor chip at 30 μl min . The single-cycle kinetic/affinity protocol was used in all binding studies. After each analysis cycle, the sensor chip was regenerated with a buffer containing 6 M guanidine hydrochloride and 0.25 M NaOH. All measurements were duplicated under the same conditions. The binding affinities (K d ) were determined by fitting the data to a steady-state 1:1 binding model using Biacore X100 Evaluation software version 2.0 (GE Healthcare). Crystallization, data collection and structure determination. Purified TBK1 was concentrated to 12 mg ml −1 and its inhibitor BX795 was added to the samples at a final concentration of 200 μM. Human TBK1 (residue 1-657, S172E, D135N) with human STING CTD (residues 155-379, T376E, F378M and S379W) or selenomethionine-labelled human STING CTT (residue 342-379, T376E, F378M and S379W) were mixed at 1:1.1 molar ratio. Crystals were obtained by mixing the complexes with equal volume reservoir buffer containing 0.8 M (NH 4 ) 2 SO 4 , 0.1 M Bis-Tris, pH 5.5, and 1% PEG3350. Mouse TBK1 (residue 1-657, S172A) was mixed human STING CTT (residue 342-379, V343W) in a 1:3 molar ratio with a final concentration of TBK1 at ~8 mg ml −1
. The complex crystals were grown in 18% (v/v) tacsimate pH 7.0, 0.1 M HEPES, pH 7.0, 2% PEG3350. The proteins were crystallized by hanging drop vapour diffusion method at 4 °C. The crystals were flash-frozen in liquid nitrogen in the reservoir solution containing 25% (v/v) glycerol. Diffraction data for the hTBK1-hSTING CTD and mTBK1-hSTING CTT complexes were collected at the Advanced Light Source (ALS) beamline 5.0.2 using a Pilatus3 6M detector. Diffraction data for the hTBK1-hSTING CTT Se-Met derivative complex were collected at ALS beamline 8.2.2 using a Quantum 315R detector. The diffraction data were processed with imosflm 26 . Both of the structures were determined by molecular replacement using either human (PDB code 4IM2) or mouse TBK1 (PDB code 4JLC) structures as search models using the Phenix package 27 . Electron density corresponds to the C-terminal 15 residues of STING are obvious in the difference maps. To facilitate model building, diffraction data at high energy Se wavelength were collected to locate Se atoms in the STING peptide. The heavy atom substructure was determined using SHELXD and the experimental phases calculated with SHELXE
28
. Three obvious heavy atom peaks were located in the anomalous difference maps calculated with model phases or experimental phases. The STING peptides were modelled with Coot
29
. The structures were refined using the Phenix package 27 . All structural figures were generated with PyMOL (https://www.pymol.org). Generation of TBK1-knockout HEK293T cells. FL-Cas9 lentivirus was produced by transfecting Lenti-X cells (Clontech) with lentiCas9-Blast 30 , second generation lentiviral packaging plasmids, and PolyJet (SignaGen) according to the manufacturer's instructions. HEK293T cells were transduced with Cas9 lentivirus with 1:1,000 Lipofectamine 2000 (Thermo Fisher Scientific) for two consecutive days and selected with 10 μg ml −1 blasticidin (Invivogen). FL-Cas9 expression was verified by western blot analysis. To ensure creation of nonsense mutations early in the coding region, TBK1-specific guide RNAs (gRNAs) were designed against the first four coding exons of TBK1 using the sgRNA Design Tool (Broad Institute): gRNA-TBK1-1: ATCACTTCTTTATTCCTACG; gRNA-TBK1-2: CATAAGCTTCCTTCGTCCAG; gRNA-TBK1-3: GAAGAACCTTCTAATGCC TA; gRNA-TBK1-4: ACAGTTGATCTTTGGAGCAT. GFP-targeting gRNAs were used as negative controls: gRNA-GFP-1: GGGCGAGGAGCTGTTCACCG; gRNA-GFP-2: CAGGGTCAGCTTGCCGTAGG; gRNA-GFP-3: AAGTTCA GCGTGTCCGGCGA. Forward and reverse primers (Integrated DNA Technologies) were cloned into lentiCRISPRv2 as previously described 30 . gRNA lentivirus was produced as above, and FL-Cas9 HEK293Ts were transduced with gRNA virus and then selected with 0.5 μg ml −1 puromycin (Invivogen). TBK1 knockout was verified by western blot analysis for endogenous TBK1 (Cell Signaling, 3013). LentiCas9-Blast and lentiCRISPR v2 were gifts from F. Zhang (Addgene plasmids 52962 and 52961). psPAX2 and pMD2.G (lentiviral packaging plasmids) were gifts from D. Trono (Addgene plasmids 12260 and 12259) . Electron microscopy. Before cryo-EM imaging, the full-length STING sample in 0.1% DDM was exchanged into Amphipol A8-35. In brief, STING at approximately 1 mg ml −1 was incubated for around 8 h with threefold excess by mass of A8-35. DDM was removed by incubation with Bio-Beads SM-2 (Bio-Rad) overnight at 15 mg Bio-Beads per millilitre of solution. The sample was filtered to remove Bio-Beads and purified using a Superose 6 increase 10/300 GL column eluted with a buffer containing 20 mM Tris, 150 mM NaCl and 5 μM cGAMP at pH 7.5. For cryo-EM imaging, 3 μl of STING at a concentration of 0.6 mg ml −1 stabilized with A8-35 was applied to glow-discharged C-flat holey carbon grids (1.2/1.3, 400 mesh). Girds were blotted for 8 s and plunge frozen in liquid ethane using a Vitrobot. Images were recorded by Latitude on a Titan Krios Transmission Electron Microscope operating at 300 kV. A Gatan K3 detector was used in counting mode at a nominal magnification of ×64,000 (yielding a pixel size of 1.42 Å). The dose rate on the camera was set to be 23.8 electrons per physical pixel per second. Exposure of 8.4 s was dose-fractionated into 84 movie frames, leading to a total accumulated dose of 100 electrons per Å 2 on the specimen. Images were recorded with a defocus in the range from 1.0 to 4.0 μm. Movies were collected with 15° and 30° tilt to address the preferred orientation of particle distribution. A total of 3,956 movies were recorded. The cryo-EM images were subjected to MotionCor2 for whole-frame dose-weighted motion correction. Particles picking was performed automatically on the summed images in Gautomatch. A total of 880,703 particles were picked. Per-particle local CTFs were estimated by GCTF. Two rounds of 2D classification were then preformed. After discarding bad class averages, 352,286 particles were re-centred and re-extracted to Relion 3D classification. Initial models for reconstruction were generated from scratch by the EMAN2 'e2initialmodel.py' program using selected unsupervised 2D averages of good quality based on visual comparison without applying any symmetry. A stack of 47,474 particles was selected to Relion 3D refinement using a 40 Å low-pass filtered reconstruction from the initial model. The final 3D reconstruction of STING oligomer with cGAMP has an overall resolution of 11.6 Å, using gold-standard Fourier shell correlation (FSC) = 0.143 criteria. The cryo-EM maps of STING oligomer was segmented using Segger. We took advantage of the availability of crystal structure of hSTING cytosolic region with cGAMP to guide the decision on the final segmentation choice. After applying the smoothing procedure for four steps to the original electron microscopy map, four regions were obtained. STING CTD structures were docked to the segmentation map using Chimera. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Atomic coordinates and structure factors of human TBK1 in complex with the human STING CTD EMW mutant, and mouse TBK1 in complex with the human STING CTT have been deposited in the Protein Data Bank (PDB) with accession codes 6O8B and 6O8C, respectively. Data in p and q are mean ± s.e.m. and representative of three independent experiments. Each dot represents a technical replicate (n = 3 in p and n = 6 in q). **P < 0.01, ***P < 0.001, two-tailed Student's t-test. NS, not significant. 
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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The atomic coordinates of the crystal structures have been deposited in the wwPDB with access codes: 6O8B and 6O8C
